Micheliolide and ACT001 as Covalent Modulators of Inflammation–Redox–Metabolism Networks in CNS Disorders: An Evidence-Stratified Review of Mechanisms and Translational Challenges
Dongqing Jing, Hongshang Chu · 2026
Read Micheliolide and ACT001 as Covalent Modulators of Inflammation–Redox–Metabolism Networks in CNS Disorders: An Evidence-Stratified Review of Mechanisms and Translational Challenges by Dongqing Jing, Hongshang Chu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13590259.txt.
Description
Dongqing Jing and Hongshang Chu review a natural compound called micheliolide and its drug form ACT001 as treatments aimed at brain disorders. Their review came out in 2026. The compound binds permanently to its targets, a strategy called covalent modulation, and touches inflammation, oxidation balance, and metabolism at once.
Evidence is strongest for the inflammation axis, with direct binding shown and consistent results across brain injury, Parkinson's disease, nerve pain, and a brain tumor type. The oxidation axis looks plausible but rests mostly on studies outside the brain. The metabolism axis is newest, with one strong direct result in the tumor setting. The authors sort diseases by which axis dominates in each. They flag open questions on drug levels in the brain and the long-term safety of permanent binding.
Catalog record
| CREATOR | Dongqing Jing, Hongshang Chu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 82 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |